Cogent Biosciences Announces Positive Top-Line Results Achieving Statistical Significance Across All Primary And Key Secondary Endpoints From The SUMMIT Trial Of Bezuclastinib In Patients With Non-Advanced Systemic Mastocytosis

Press/Media

Period7 Jul 2025

Media coverage

1

Media coverage

  • TitleCogent Biosciences Announces Positive Top-Line Results Achieving Statistical Significance Across All Primary And Key Secondary Endpoints From The SUMMIT Trial Of Bezuclastinib In Patients With Non-Advanced Systemic Mastocytosis
    Media name/outletMENAFN - Press Releases (English)
    Country/TerritoryJordan
    Date7/07/25
    PersonsNathan Boggs
View all 1
View less